[ORGANIZATION]
Novo Nordisk A/S
Featured in 10 tracked stories · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
112 clusters · 548 sources · last updated
Latest: Novo Nordisk faces intense competition in obesity drug market
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,
Also covered in
-
PepsiCo to end employee coverage for weight-loss drugs
[BUSINESS] · 2 sources ·
-
Pfizer's berobenatide weight‑loss drug draws market attention
[BUSINESS] · 3 sources ·
-
Royal Bank of Canada boosts stakes in Sanofi and Novo Nordisk
[BUSINESS] · 2 sources ·